Pearl River Capital, LLC Incyte Corp Transaction History

Pearl River Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$52.16 - $64.19 $1.68 Million - $2.06 Million	-32,156 Reduced 56.43%	24,824 $1.56 Million
Q3 2023 Nov 13, 2023	BUY	$57.77 - $65.93 $3.29 Million - $3.76 Million	56,980 New	56,980 $3.29 Million
Q4 2021 Feb 11, 2022	SELL	$63.34 - $74.11 $1.06 Million - $1.24 Million	-16,765 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $1.15 Million - $1.41 Million	16,765 New	16,765 $1.15 Million
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $849,223 - $1.03 Million	-10,518 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $894,766 - $1.15 Million	10,518 New	10,518 $944,000
Q2 2020 Aug 10, 2020	SELL	$74.18 - $108.93 $47,771 - $70,150	-644 Closed	0 $0
Q1 2020 May 06, 2020	BUY	$63.18 - $85.97 $40,687 - $55,364	644 New	644 $47,000
Q2 2019 Aug 12, 2019	SELL	$73.52 - $88.7 $58,963 - $71,137	-802 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$63.56 - $88.17 $50,975 - $70,712	802 New	802 $68,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.